Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. - Wikidata - wikimedia - TriplyDB

Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.

Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.

http://www.wikidata.org/entity/Q35195203

about

Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis Current antiplatelet treatment strategy in patients with diabetes mellitus.Increased Benefit With Vorapaxar Use in Patients With a History of Myocardial Infarction and Diabetes Mellitus: What the Data Show Us.Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.Vorapaxar: a review of its use in the long-term secondary prevention of atherothrombotic events.Investigational new drugs for the treatment of acute coronary syndrome.Review of vorapaxar for the prevention of atherothrombotic events.Vorapaxar in the secondary prevention of atherothrombosis.Percutaneous Coronary Intervention: 2015 in Review.Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease.Targeting PAR1: Now What?Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention.Platelets: an outlook from biology through evidence-based achievements in critical care.Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease.Vorapaxar in secondary prevention: where we stand.Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice.Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease

P2860

Q26745754-D575BA11-59D2-4699-BF81-5C955E514E2D Q26783034-DF010C60-FCC0-4B37-B28B-6F7553C6E97D Q35544048-8C758630-4BEE-4579-B7A2-46C7967CE73B Q36094523-D2ABE9C5-91F2-4F31-97DA-8E105EBD0C32 Q37011769-4991F81F-57E0-4535-BAF5-83EF5E5D2F03 Q38402334-82AD8BB9-B308-4615-9CC7-C03BBBD868F3 Q38431157-17D08D4A-C9AB-4374-B165-32183FBF37D3 Q38594609-0171B80B-FE7B-46B4-B740-5DEE55F54579 Q38610947-A43B5B31-2EFE-4E3C-8AA8-E6D4DBF31D05 Q38630968-B31F43C1-07F5-4BA5-A0C8-32452ABD36CD Q38728869-4EBA468F-EF2F-43B3-B49B-E137E1E969D4 Q38773641-DF6F8B50-2BCF-42A3-9CFC-2EF625C28BDC Q39338913-FD7F89A1-050F-4858-B3EF-74AD4C3AEA62 Q41250240-A9917D2B-91E9-4C23-BE06-1F56855C633E Q47178294-87B1909D-3072-46C3-8B85-53E3390E7E01 Q47676770-7D8F0F7F-DA93-4E7C-8450-4A36DE0EED8B Q48293958-391A2663-A3AD-474B-B5C4-A2E3D3189860 Q54974290-40765035-386E-4E79-B29A-9C67CF52F9E7 Q56384060-AD65F04B-E274-449A-B3C2-7729DE31401A

P2860

Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.

http://www.wikidata.org/entity/Q35195203

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Vorapaxar in patients with dia ...... ischemic events-TIMI 50 trial.

@ast

Vorapaxar in patients with dia ...... ischemic events-TIMI 50 trial.

@en

type

label

Vorapaxar in patients with dia ...... ischemic events-TIMI 50 trial.

@ast

Vorapaxar in patients with dia ...... ischemic events-TIMI 50 trial.

@en

prefLabel

Vorapaxar in patients with dia ...... ischemic events-TIMI 50 trial.

@ast

Vorapaxar in patients with dia ...... ischemic events-TIMI 50 trial.

@en

P1433

Q35195203-F11D5245-99AB-4013-94A5-52A079534F8E

P1476

Q35195203-860E8866-2EDC-46AE-8343-EB8E540B7E42

P2093

Q35195203-2E062CD5-0FC5-44CA-88F6-C8238EE1B9B7

Q35195203-A2BEEA00-789F-4521-AC7C-AF6622FAEBE6

Q35195203-B66283F1-E70F-4A66-9B8D-410AA2A9663C

Q35195203-BFAA99B2-4F9A-4565-BED7-1D2E94406A4C

Q35195203-DD229A1C-A644-47CA-9DB7-B47DC4479B3F

Q35195203-E18C5EE4-930C-46D5-9A3B-E938E9B69044

Q35195203-E640BBB8-EB22-4FBC-880B-7D529DC5767E

Q35195203-EF53C0D1-6471-47FB-9C8F-2BA4B0C0B537

Q35195203-F8F1712A-7411-41C5-A298-467562B47F86

P2860

Q35195203-01D67320-7FCD-440C-B0B5-494ACD2E13E5

Q35195203-049758E7-EA0F-4F60-BF9B-310351B97C94

Q35195203-107B6219-9393-4650-8BC7-E9B2DA898C42

Q35195203-138838ED-B0AC-4D7E-993D-B195574564E4

Q35195203-1820A6CA-DD4F-4F31-937E-8D3129CBE127

Q35195203-43F3A19C-C81A-412F-A476-578CA25B5AD2

Q35195203-6B755A1B-31A6-4AC6-AECC-DF2765B58495

Q35195203-74B5E06D-8BAC-4D1D-AD9F-90955EF9BA16

Q35195203-868D14D5-0B25-4A8E-8B29-A774B00A272A

Q35195203-8BD82874-48DD-4953-BF84-36D466476058

P304

Q35195203-88C6EAB1-CBE3-46FC-9D75-7259EFD56B93

P31

Q35195203-F44535A7-49CC-42C9-BF33-B24FE9FA2F51

P356

Q35195203-68E14734-F5DB-4ED8-9311-8A7B7AEE9FA8

P407

Q35195203-83531D8A-CC52-47A7-865C-452040C3547B

P433

Q35195203-341FA5A8-F17E-4B28-A7ED-714335449461

P478

Q35195203-6D0770F7-E062-4EDD-B8C4-E63C53DB7C79

P50

Q35195203-019BC740-B287-4029-993E-498E4CDB68A5

Q35195203-8A38A24F-D532-4987-870E-C0BB92838408

Q35195203-DF2BFE7F-CE88-4557-A6EB-0E4BCCC69DB5

P577

Q35195203-DC48D173-DA29-4AC2-8A01-B41F274D7E6F

P5875

Q35195203-9C35EAD2-2B54-4143-8E4A-44760FD37742

P698

Q35195203-34DA6E6D-EC4C-4E35-BBCA-1B265FC9317C

P932

Q35195203-4EB628D3-74BA-476B-A2CB-484193344991

P356

CIRCULATIONAHA.114.013774

P1433

P1476

Vorapaxar in patients with dia ...... ischemic events-TIMI 50 trial.

@en

P2093

Anthony J Dalby

http://www.w3.org/2001/XMLSchema#string

Benjamin M Scirica

http://www.w3.org/2001/XMLSchema#string

David A Morrow

http://www.w3.org/2001/XMLSchema#string

Dominick J Angiolillo

http://www.w3.org/2001/XMLSchema#string

Marc P Bonaca

http://www.w3.org/2001/XMLSchema#string

Matthew A Cavender

http://www.w3.org/2001/XMLSchema#string

Mikael Dellborg

http://www.w3.org/2001/XMLSchema#string

Sabina A Murphy

http://www.w3.org/2001/XMLSchema#string

Ton Oude Ophuis

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

The platelet in diabetes: focus on prevention of ischemic events

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

Vorapaxar in the secondary prevention of atherothrombotic events.

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.

Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study

Diabetes and antiplatelet therapy in acute coronary syndrome.

Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis.

Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study.

P304

1047-1053

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.114.013774

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

131

http://www.w3.org/2001/XMLSchema#string

P50

Eugene Braunwald

Michał Tendera

P577

2015-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272297108

http://www.w3.org/2001/XMLSchema#string

P698

25681464

http://www.w3.org/2001/XMLSchema#string

P932

4365950

http://www.w3.org/2001/XMLSchema#string